Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
9 Jun 2021

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )
9 Jun 2021

Can multiple endpoints in MM clinical papers create new insights?

Prof Evangelos Terpos and Prof Nina Shah
Can multiple endpoints in MM clinical papers create new insights? ( Prof Evangelos Terpos and Prof Nina Shah )
9 Jun 2021

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )
8 Jun 2021

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Jun 2021

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
8 Jun 2021

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

Dr Joshua Sabari and Dr Anna Minchom
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )
8 Jun 2021

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma

Prof Daniel Catenacci - University of Chicago, Chicago, USA
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )
5 Jun 2021

Clinical trials participation is directly influenced by the information received by cancer patients and caregivers

Dr Daniel Vorobiof - Belong.Life, New York, USA
Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )
4 Jun 2021